Neurogene Inc. executives and directors have only been selling lately: four insiders trimmed about $1.1 million of stock over 12 months, with no open-market purchases.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
On the institutional side, 112 funds reported holding NGNE at the end of Q2 2026, and more funds bought than sold. 3 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine Mikail | CFO | Sell | 600 | $36.02 | $22K | SEC |
| Jul 7, 2026 | Cvijic Christine Mikail | CFO | Sell | 4,200 | $36.13 | $152K | SEC |
| Jul 2, 2026 | Cvijic Christine Mikail | CFO | Sell | 739 | $34.06 | $25K | SEC |
| Jul 2, 2026 | Cvijic Christine Mikail | CFO | Sell | 2,531 | $34.58 | $88K | SEC |
| Jul 2, 2026 | Cvijic Christine Mikail | CFO | Sell | 1,530 | $35.23 | $54K | SEC |
| May 8, 2026 | Cvijic Christine Mikail | CFO | Sell | 4,800 | $32.44 | $156K | SEC |
| May 8, 2026 | Cvijic Christine Mikail | CFO | Sell | 4,800 | $30.07 | $144K | SEC |
| Mar 30, 2026 | Cvijic Christine Mikail | CFO | Sell | 2,558 | $21.62 | $55K | SEC |
| Mar 30, 2026 | McMinn Rachel | CEO | Sell | 3,352 | $22.07 | $74K | SEC |
| Mar 30, 2026 | Jordan Julie | Executive Officer | Sell | 828 | $21.89 | $18K | SEC |
| Mar 17, 2026 | Cobb Stuart | Executive Officer | Sell | 2,658 | $21.34 | $57K | SEC |
| Mar 17, 2026 | Cobb Stuart | Executive Officer | Sell | 3,991 | $20.41 | $81K | SEC |
| Mar 17, 2026 | Cobb Stuart | Executive Officer | Sell | 148 | $22.08 | $3K | SEC |
| Mar 17, 2026 | Cvijic Christine Mikail | CFO | Sell | 263 | $22.02 | $6K | SEC |
| Mar 17, 2026 | Cvijic Christine Mikail | CFO | Sell | 1,395 | $21.25 | $30K | SEC |
In the last 12 months Neurogene Inc. insiders made open-market purchases worth about $0 and sales worth about $1.1 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in NGNE was filed on 2026-07-07.
112 investment managers reported holding NGNE in SEC Form 13F filings for Q2 2026.
No congressional trades in NGNE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).